A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients
PeerJ · 2026
DOI: 10.7717/peerj.20536 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PeerJ, 2026. Verfasst von Liying Gong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Blood Platelets, Receptors, Purinergic P2Y12. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Project of Hunan Province, National Major New Drug Creation Project of China, Health Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
Background
Much evidence has been provided that a therapeutic window of P2Y 12 receptor inhibition exists, which is highly significantly associated with ischemic and bleeding events. The therapeutic window for high-risk stratification after percutaneous coronary intervention (PCI) is lacking. We aimed to investigate the therapeutic window of P2Y 12 receptor inhibition in high-risk Chinese PCI patients.
Methods
In this observational study, we analyzed 860 high-risk patients who were undergoing PCI. The primary endpoint was the correlation between vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) values with bleeding and ischemic components in high-risk patients. The secondary endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, urgent revascularization, and stroke at 12 months after the index procedure.
Results
Among high-risk patients, VASP-PRI could significantly discriminate between PCI patients with and without ischemic events (area under the curve (AUC): 0.77; 95% CI [0.72–0.82]; P < 0.001). A VASP-PRI ≥ 0.45 was the optimal cutoff point to predict ischemic events (sensitivity: 86.6%; specificity: 63.6%). Similarly, VASP-PRI could also significantly discriminate between PCI patients with and without bleeding events ((AUC): 0.77; 95% CI [0.73–0.81]; P < 0.001). A VASP-PRI ≤ 0.24 was the optimal cutoff point to predict bleeding events (sensitivity: 72.1%; specificity: 70.3%). Multivariate analysis showed that VASP-PRI was an independent predictor of the risk of major adverse cardiovascular events (odds ratio: 10.67, 95% CI [3.78–30.08]).
Conclusion
Our results suggest that high-risk Chinese PCI patients have a narrow therapeutic window. Within this window, high-risk patients are at lower risk for both ischemic and bleeding events. Platelet reactivity may have significant implications for personalized antiplatelet therapy in high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of the Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsh, China.
- Department of the Clinical Hematology Laboratory, The Third Xiangya Hospital, Central South University, Changsha, China.
- XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, China.
Förderung
- Key Research and Development Project of Hunan Province
- National Major New Drug Creation Project of China
- Health Research Project of Hunan Provincial Health Commission
Zitieren
APA
Gong, L., Liu, Y., Li, J., Tan, S., Guo, C., Wang, Z., Song, H., Kuang, Y., Cao, Y., & Yang, G. (2026). A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients. PeerJ. https://doi.org/10.7717/peerj.20536
Vancouver
Gong L, Liu Y, Li J, Tan S, Guo C, Wang Z, et al. A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients. PeerJ. 2026. doi:10.7717/peerj.20536
BibTeX
@article{Gong2026,
author = {Gong, Liying and Liu, Yaxin and Li, Jingle and Tan, Shiming and Guo, Chengxian and Wang, Zhengmei and Song, Huiling and Kuang, Yun and Cao, Yu and Yang, Guoping},
title = {A narrow therapeutic window of platelet P2Y 12 reactivity in high-risk Chinese percutaneous coronary intervention patients},
journal = {PeerJ},
year = {2026},
doi = {10.7717/peerj.20536}
}
EUVIMED